These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

265 related items for PubMed ID: 25775877

  • 1. [PREVFNAIT prevention of foetal/neonatal alloimmune thrombocytopenia (FNAIT) in Polish foetuses and newborns--the PREVFNAIT program].
    Uhrynowska ME, Dębska M, Guz K, Orzińska A, Wróbel A, Maślanka K, Dębski R, Brojer E.
    Ginekol Pol; 2015 Jan; 86(1):62-6. PubMed ID: 25775877
    [Abstract] [Full Text] [Related]

  • 2. Fetal and Neonatal Alloimmune Thrombocytopenia-New Prospects for Fetal Risk Assessment of HPA-1a-Negative Pregnant Women.
    Kjeldsen-Kragh J, Bengtsson J.
    Transfus Med Rev; 2020 Oct; 34(4):270-276. PubMed ID: 33039264
    [Abstract] [Full Text] [Related]

  • 3. Prenatal Management of Pregnancies at Risk of Fetal Neonatal Alloimmune Thrombocytopenia (FNAIT): Scientific Impact Paper No. 61.
    Regan F, Lees CC, Jones B, Nicolaides KH, Wimalasundera RC, Mijovic A, Royal College of Obstetricians and Gynaecologists.
    BJOG; 2019 Sep; 126(10):e173-e185. PubMed ID: 30968555
    [Abstract] [Full Text] [Related]

  • 4. Fetal/Neonatal Alloimmune Thrombocytopenia: Pathogenesis, Diagnostics and Prevention.
    Brojer E, Husebekk A, Dębska M, Uhrynowska M, Guz K, Orzińska A, Dębski R, Maślanka K.
    Arch Immunol Ther Exp (Warsz); 2016 Aug; 64(4):279-90. PubMed ID: 26564154
    [Abstract] [Full Text] [Related]

  • 5. Anti-human platelet antigen-5b antibodies and fetal and neonatal alloimmune thrombocytopenia; incidental association or cause and effect?
    Alm J, Duong Y, Wienzek-Lischka S, Cooper N, Santoso S, Sachs UJ, Kiefel V, Bein G.
    Br J Haematol; 2022 Jul; 198(1):14-23. PubMed ID: 35383895
    [Abstract] [Full Text] [Related]

  • 6. What's with the boys? Lower birth weight in boys from HPA-1a alloimmunized pregnancies - New insights from a large prospective screening study in Poland.
    Coucheron T, Uhrynowska M, Guz K, Orzińska A, Debska M, Gierszon A, Ahlen MT, Bertelsen EL, Berge G, Husebekk A, Brojer E, Tiller H.
    J Reprod Immunol; 2023 Dec; 160():104168. PubMed ID: 37992463
    [Abstract] [Full Text] [Related]

  • 7. Strategies to develop a prophylaxis for the prevention of HPA-1a immunization and fetal and neonatal alloimmune thrombocytopenia.
    Kjær M, Geisen C, Akkök ÇA, Wikman A, Sachs U, Bussel JB, Nielsen K, Walles K, Curtis BR, Vidarsson G, Järås K, Skogen B.
    Transfus Apher Sci; 2020 Feb; 59(1):102712. PubMed ID: 31948915
    [Abstract] [Full Text] [Related]

  • 8. Clinical characteristics of human platelet antigen (HPA)-1a and HPA-5b alloimmunised pregnancies and the association between platelet HPA-5b antibodies and symptomatic fetal neonatal alloimmune thrombocytopenia.
    de Vos TW, Porcelijn L, Hofstede-van Egmond S, Pajkrt E, Oepkes D, Lopriore E, van der Schoot CE, Winkelhorst D, de Haas M.
    Br J Haematol; 2021 Nov; 195(4):595-603. PubMed ID: 34402048
    [Abstract] [Full Text] [Related]

  • 9. Toward a prophylaxis against fetal and neonatal alloimmune thrombocytopenia: induction of antibody-mediated immune suppression and prevention of severe clinical complications in a murine model.
    Tiller H, Killie MK, Chen P, Eksteen M, Husebekk A, Skogen B, Kjeldsen-Kragh J, Ni H.
    Transfusion; 2012 Jul; 52(7):1446-57. PubMed ID: 22251227
    [Abstract] [Full Text] [Related]

  • 10. An HPA-1a-positive platelet-depleting agent for prevention of fetal and neonatal alloimmune thrombocytopenia: a randomized, single-blind, placebo-controlled, single-center, phase 1/2 proof-of-concept study.
    Geisen C, Kjaer M, Fleck E, Skogen B, Armstrong R, Behrens F, Bhagwagar Z, Braeuninger S, Mortberg A, Olsen KJ, Gastón Schäfer SM, Walter C, Seifried E, Wikman A, Kjeldsen-Kragh J, Koehm M.
    J Thromb Haemost; 2023 Apr; 21(4):838-849. PubMed ID: 36696185
    [Abstract] [Full Text] [Related]

  • 11. Maternal HPA-1a antibody level and its role in predicting the severity of Fetal/Neonatal Alloimmune Thrombocytopenia: a systematic review.
    Kjaer M, Bertrand G, Bakchoul T, Massey E, Baker JM, Lieberman L, Tanael S, Greinacher A, Murphy MF, Arnold DM, Baidya S, Bussel J, Hume H, Kaplan C, Oepkes D, Ryan G, Savoia H, Shehata N, Kjeldsen-Kragh J, International Collaboration for Transfusion Medicine Guidelines.
    Vox Sang; 2019 Jan; 114(1):79-94. PubMed ID: 30565711
    [Abstract] [Full Text] [Related]

  • 12. Towards a prophylactic treatment of HPA-related foetal and neonatal alloimmune thrombocytopenia.
    Kjeldsen-Kragh J, Ni H, Skogen B.
    Curr Opin Hematol; 2012 Nov; 19(6):469-74. PubMed ID: 22954726
    [Abstract] [Full Text] [Related]

  • 13. HIP (HPA-screening in pregnancy) study: protocol of a nationwide, prospective and observational study to assess incidence and natural history of fetal/neonatal alloimmune thrombocytopenia and identifying pregnancies at risk.
    Winkelhorst D, de Vos TW, Kamphuis MM, Porcelijn L, Lopriore E, Oepkes D, van der Schoot CE, de Haas M.
    BMJ Open; 2020 Jul 20; 10(7):e034071. PubMed ID: 32690731
    [Abstract] [Full Text] [Related]

  • 14. Fetal and neonatal alloimmune thrombocytopenia: a late or missed diagnosis disease in fetal and perinatal health-care settings.
    Blanco S, Vega LC, Carrizo LH, Culasso JM, Gallego SV.
    J Matern Fetal Neonatal Med; 2022 Jan 20; 35(2):263-268. PubMed ID: 31973628
    [Abstract] [Full Text] [Related]

  • 15. Maternal antibodies against paternal class I human leukocyte antigens are not associated with foetal and neonatal alloimmune thrombocytopenia.
    Sachs UJ, Wienzek-Lischka S, Duong Y, Qiu D, Hinrichs W, Cooper N, Santoso S, Bayat B, Bein G.
    Br J Haematol; 2020 May 20; 189(4):751-759. PubMed ID: 31997312
    [Abstract] [Full Text] [Related]

  • 16. [Establishing a screening programme in Denmark for foetal and neonatal alloimmune thrombocytopenia].
    Madsen C, Prahm KP, Nilsson C, Pedersen LH, Dziegiel MH, Hedegaard M.
    Ugeskr Laeger; 2018 Apr 23; 180(17):. PubMed ID: 29717700
    [Abstract] [Full Text] [Related]

  • 17. Compound heterozygosity of HLA-DRB3*01:01 and HLA-DRB4*01:01 as a potential predictor of fetal neonatal alloimmune thrombocytopenia.
    Loewenthal R, Rosenberg N, Kalt R, Dardik R, Landau M, Yahalom V, Avishai O, Frenkel O, Gazit E, Steinberg DM, Lipitz S, Salomon O.
    Transfusion; 2013 Feb 23; 53(2):344-52. PubMed ID: 22671039
    [Abstract] [Full Text] [Related]

  • 18. Non-invasive risk-assessment and bleeding prophylaxis with IVIG in pregnant women with a history of fetal and neonatal alloimmune thrombocytopenia: management to minimize adverse events.
    Wienzek-Lischka S, Sawazki A, Ehrhardt H, Sachs UJ, Axt-Fliedner R, Bein G.
    Arch Gynecol Obstet; 2020 Aug 23; 302(2):355-363. PubMed ID: 32495019
    [Abstract] [Full Text] [Related]

  • 19. Fetal and neonatal alloimmune thrombocytopenia.
    van den Akker ES, Oepkes D.
    Best Pract Res Clin Obstet Gynaecol; 2008 Feb 23; 22(1):3-14. PubMed ID: 17936686
    [Abstract] [Full Text] [Related]

  • 20. Fetal/neonatal allo-immune thrombocytopenia (FNAIT): past, present, and future.
    Serrarens-Janssen VM, Semmekrot BA, Novotny VM, Porcelijn L, Lotgering FK, Delemarre FM, Steegers EA.
    Obstet Gynecol Surv; 2008 Apr 23; 63(4):239-52. PubMed ID: 18348738
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 14.